U069 JAAD and Beyond: The Best Articles of the Year
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Cutting-edge advances published in JAAD, JAMA Derm, EADV and BJD will be presented with a discussion of why they are game changers.
LEARNING OBJECTIVES
Review treatment updates from the JAAD, JAMA Derm, EADV and BJD.
Discuss diagnostic updates from the JAAD, JAMA Derm, EADV and BJD.
SCHEDULE
11:30 PM
Highlights from the BJD
John Ingram, PhD, MD
11:45 PM
Highlights from the JEADV
Johannes Ring, MD, IFAAD
12:00 AM
Highlights from JAMA Derm
Kanade Shinkai, MD, PhD, FAAD
12:15 AM
Higlights from JAAD
Dirk Michael Elston, MD, FAAD
SPEAKERS
Dirk Michael Elston, MD, FAAD
John Ingram, PhD, MD
Lajos Kemeny, DSc, PhD, MD, IFAAD
Johannes Ring, MD, IFAAD
Kanade Shinkai, MD, PhD, FAAD
SPEAKER DISCLOSURES
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
John Ingram, PhD, MD
AbbVie – Consultant(Honoraria); Boehringer Ingelheim – Consultant(Honoraria); British Journal of Dermatology – Other(Honoraria); ChemoCentryx – Consultant(Honoraria); Citryll – Consultant(Honoraria); Insmed Incorporated – Advisory Board(Honoraria); Kymera Therapeutics – Advisory Board(Honoraria); Novartis – Consultant(Honoraria); UCB – Consultant(Honoraria); Viela Bio – Advisory Board(Honoraria);
Lajos Kemeny, DSc, PhD, MD, IFAAD
AbbVie – Advisory Board(Honoraria), Speaker(Honoraria); Eli Lilly and Company – Advisory Board(Honoraria), Investigator(Fees), Speaker(Honoraria); Eli-Lilly – Advisory Board(Honoraria); Eli-Lilly Ltd – Advisory Board(Honoraria); Janssen-Cilag – Advisory Board(Honoraria), Speaker(Honoraria); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Fees), Speaker(Honoraria);
Johannes Ring, MD, IFAAD
AbbVie – Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); Sanofi Genzyme – Speaker(Honoraria); Viatris Inc. – Speaker(Honoraria);
Kanade Shinkai, MD, PhD, FAAD
No financial relationships exist with ineligible companies.